Haha nice final note. Thanks for your insights!!!

First 107 Last

Share
Profile

Follow
BobbyRoyale

289 Posts.

02/01/16

12:45

Post #: 16715090
Share

Originally posted by kitehigh ↑

Hi Bobby, I will give you my thoughts.

1. Yes there is already established competition but apparently no one can offer the scale and price point that Dubber is currently offering. Dubber also provide some unique key word analytics that other providers can't provide(the banks are big on this at the moment and hence the bank deal Dubber signed recently). Dubbers technology is unique and not easily replicated.

2. Definitely suitable for a long term investment but we should get decent share price appreciation soon once the next client contract lands, which could come before the end of this month.

3. If we land the large Telco contract that we are all hanging out for(currently 25 Telco's in the testing phase in Dubber Labs), than we should easily rerate to $2 plus. So imagine what multiple Telco signings will do for the share price. I'm targeting at least $5 before the end of the year and I believe at some stage Dubber will be TO target by one of those large Telco's.

I'm super bullish on this company and have been for a long time so I will just temper that with some of the downside risk so you have a better picture.
1. An established competitor develops their own cloud software which is better than ours and due to existing client relationships with some of the bigger clients gains a much better competitive advantage over Dubber.

2. Dubber fails to sign any significant clients and continues to burn cash at an unhealthy rate( currently cash burn has been too high, hopefully with the new cornerstone investors onboard they can demand more prudent expenditure.

3. A newer technology is developed which completely makes our technology redundant and thus leaves Dubber holding a dud.

4. Complete financial meltdown, companies going bust and marshal law declared to control the zombies lol.

None of this should be taken as advice just entertainment value only!

Expand

Haha nice final note. Thanks for your insights!!!

DUB Price at posting: 71.0¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

There are more pages in this discussion • 124 more messages in this thread...

First 107 Last

Add DUB (ASX) to my watchlist

(20min delay)
Last 4.7¢		Change -0.003(6.00%)		Mkt cap ! $43.19M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$159.8K	3.245M

Buyers (Bids)

No.	Vol.	Price($)
3	373683	4.7¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	276992	2

View Market Depth

No.	Vol.	Price($)
3	373683	0.047
2	188498	0.046
4	253000	0.045
1	500000	0.044
1	250000	0.043

Price($)	Vol.	No.
0.050	276992	2
0.051	95800	4
0.052	517365	3
0.053	95000	3
0.054	135000	4

Last trade - 16.10pm 09/07/2024 (20 minute delay)

DUB (ASX) Chart

Haha nice final note. Thanks for your insights!!!

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Haha nice final note. Thanks for your insights!!!

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News